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A B S T R A C T
Sidastrum micranthum (A. St.-Hil.) Fryxell, Malvaceae, grows in the northeastern region of 
Brazil, where the leaves of this species are traditionally used to treat coughs, bronchitis or 
asthma. Male Swiss mice (20-22 g) were tested in models of acute pain (acetic acid-induced 
abdominal writhing, tail flick and formalin test), oedema assessment test (paw oedema 
test) and model for evaluation of spontaneous motor performance (open field test). The 
hydroethanolic extract of S. micranthum was administered orally at doses of 50-500 mg/kg. 
In addition were administered water, vehicle, morphine 5.01 mg/kg (evaluation of pain and 
motor performance) and dexamethasone 2.25 mg/kg (evaluation of oedema formation). The 
extract showed a significant effect at all doses in the acetic acid-induced abdominal writhing 
test and at the second phase of the formalin test, while in the first phase of this test and in 
the paw oedema test only at the highest dose (500 mg/kg). In the formalin and paw oedema 
tests, the extract had a potentiation of the anti-nociceptive and anti-inflammatory effects by 
pretreatment with L-NAME and reduction of the effect by pretreatment with L-arginine. The 
extract was not toxic after oral administration (LD50 > 2000 mg/kg). 
© 2013 Elsevier Editora Ltda. 
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Introduction
Non-steroidal anti-inflammatory drugs (NSAID) are used 
worldwide for the treatment of inflammation, pain and fever. 
However, the side effects of currently available anti-inflammatory 
drugs include gastric ulcer, renal damage, bronchospasm and 
cardiac abnormalities, which have limited their use (Burke et 
al., 2006). Opioids are one of the most powerful drugs for the 
treatment of pain, nevertheless adverse side effects have limited 
their use also (Butler et al., 2004). Efforts to eliminate or minimize 
the undesired adverse effects have led to the search for medicinal 
plants derived natural products (Cowan et al., 2002; Gilson et 
al., 2004). In recent years, many researchers have focused on 
medicinal plants-derived natural products such as flavonoids, 
steroids, polyphenols, coumarins, terpenes and alkaloids, due to 
their wide range of pharmacological applications including anti-
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inflammatory, analgesic and antipyretic activities with lesser side 
effects (Shukla et al., 2010).
Traditional medicine is used throughout the world and has 
rapidly gained growing economic importance, where modern 
health services are limited, particularly in developing countries. In 
these countries traditional medicine represents the only accessible 
treatment (Agra et al., 2007).
According to estimates by the World Health Organization 
(WHO, 1999), in many developed countries, a high proportion 
of the population uses traditional health practices, especially 
medicinal plants. Although access to modern medicine is 
available in these countries, the use of medicinal herbs has 
retained popularity for historical and cultural reasons. 
The Malvaceae family consists of 243 genera and 4225 
species distributed around the world, predominantly in South 
America (Gomes et al., 2011b). Sidastrum micranthum is an erect 
shrub, 2-3 m high with a stem up to 4 cm in diameter at base 
(Shimpale et al., 2009). In Brazil, Sidastrum micranthum (A. St.-
Hil.) Fryxell, Malvaceae, appears mostly in the northeast region, 
where the leaves of this species are traditionally used to treat 
coughs, bronchitis, asthma and rheumatism, among other 
conditions (Fryxell, 1997). Rural communities in this area do 
not have access to immediate medical treatment and for this 
reason the hydroethanolic extract obtained from the leaves 
of S. micranthum is extensively used. In Brazil, S. micranthum 
is commonly known by several names: malva-preta, relógio, 
vassoura-de-relógio, vassourinha, malva, vassoura-do-campo, 
guanxuma and mata-pasto (Wagner et al., 1999). 
Gomes et al. (2011a) reported the isolation of the triterpene 
isoarborinol β-sitosterol and the glycosylated steroid 3-O-β-D-
glucopyranoside, from S. micranthum leaves. β-sitosterol and 
stigmasterol mixture, isolated from S. paniculatum, showed 
a significant anti-inflammatory activity (Cavalcante et al., 
2010). Triterpenes and steroids may be responsible for anti-
inflammatory and anti-nociceptive effects, properties extensively 
documented in the literature (Diaz et al., 2000; Gaertner et al., 
1999; Geetha and Varalakshmi, 2001; Santos et al., 1995).
The species Sidastrum micranthum, despite its popular 
use, has not been presented with scientific evidence of its 
effects, especially those related to the control of pain and 
inflammation. Based on the results of an ethnobotanical 
survey conducted among traditional medicine practitioners, 
the aim of this study is to evaluate the anti-nociceptive and 
anti-oedematogenic activity of the hydroethanolic extract of 
Sidastrum micranthum leaves in mice.
Materials and methods
Plant material
The leaves of Sidastrum micranthum (A. St.-Hil.) Fryxell, 
Malvaceae, were collected in the city of Muniz Freire, ES, 
Brazil (20º 26’ 19’’ S e 41º 23’ 44’’ W) in March 2009. The plant 
was authenticated by Érika Von Sohsten de Souza Medeiros 
(Departamento de Botânica Sistemática, Jardim Botânico do 
Rio de Janeiro, Brazil) and a voucher specimen was deposited 
in the Herbarium of the Botanical Garden under the number 
RB492872. 
Preparation of the plant extract
The leaves (200 g) were grounded and extracted with 70% 
hydroethanolic solution for 72 h, filtered and subjected for 
further extraction for the same amount of time. The filtrates 
were concentrated in a rotary vacuum evaporator, to obtain 
the crude hydroethanolic extract. The yield of the extract was 
about 23% (w/w). The material was stored at -20°C until use.
Phytochemical analysis
The material was partitioned with n-hexane, chloroform, 
ethyl acetate and n-buthanol. The n-hexane phase was 
subjected to column chromatography with 7734 silica gel 60, 
and eluted with n-hexane, ethyl acetate and then methanol, 
gradually increasing the polarity. The identification of the 
chemical constituents was performed through spectra analysis 
by infrared and nuclear magnetic resonance 1H and 13C 
spectroscopy using uni and bi-dimensional techniques, and 
compared results with the literature. 
Chemicals
The following substances were used: acetic acid (Vetec, Rio 
de Janeiro, Brazil), formalin (Merck, Darmstadt, Germany), 
dexamethasone, L-NAME, L-arginine, mecamylamine, atropine, 
λ-carrageenan, 70% ethanol and dimethyl sulfoxide (Sigma-
Aldrich, St. Louis, MO, USA), morphine and naloxone (Cristália, 
São Paulo, Brazil). 
Animals 
Male Swiss mice (20-22 g) were obtained from the housing 
facilities of the Department of Physiological Sciences of the 
Federal Rural University of Rio de Janeiro. The animals were 
maintained in a room with controlled temperature (22 ± 
2°C) and a 12 h light/dark cycle with free access to food and 
water. Twelve hours before each experiment, the animals 
received only water, to avoid possible interference of food 
with the absorption of the drug. The experimental protocol 
was approved by the Ethics Committee for Animal Research of 
the Federal Rural University of Rio de Janeiro (COMEP-UFRRJ) 
(23083.004724/2011-16).
Treatments
Increasing doses of the extract were administered orally (50, 
100, 300 and 500 mg/kg p.o.). Morphine and dexamethasone 
were used as positive controls. The doses of the opioid 
analgesic, morphine (5.01 (2.47-8.68) mg/kg, p.o.) and the 
steroidal anti-inflammatory, dexamethasone (2.25 (1.82-
2.79) mg/kg, s.c.) were obtained by ED50 (confidence limits) 
calculation in acetic acid-induced abdominal writhing and 
paw edema tests, that were performed beforehand. The ED50 
value (the dose producing 50% of the maximal effect) for the 
anti-nociceptive and anti-oedematogenic actions was obtained 
by nonlinear regression (sigmoidal dose response) (data not 
shown). 
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Distilled water mixed with dimethyl sulfoxide (solubilizing 
agent) was used as a vehicle (5%), for the preparation of 
different doses of the extract. The control group consisted of 
mice that received only distilled water. 
To evaluate the participation of particular systems (opioid, 
muscarinic, nicotinic and nitrergic) on the effect shown by 
Sidastrum micranthum extract, naloxone (5 mg/kg), atropine 
(10 mg/kg), mecamylamine (10 mg/kg), L-NAME (20 mg/kg) 
and L-arginine (40 mg/kg) were administered intraperitoneally 
(i.p.) 15 min before the oral administration of the extract. 
Antagonists’ doses were chosen by comparison of increasing 
doses of the antagonist against a single Sidastrum micranthum 
extract concentration. Antagonists were administered before 
standard reference drugs to verify the specificity and selectivity 
of these substances to the test and doses used. The doses were 
chosen for the highest ability to elicit the anti-nociceptive 
effects produced by extract without producing activity.
Acetic acid-induced abdominal writhing test
In order to evaluate the anti-nociceptive effect of the plant 
extract, different groups were treated orally with vehicle, water, 
morphine or extract (at increasing doses) 60 min before the i.p. 
acetic acid injection. The behavioural protocol was performed 
as previously described by Koster et al. (1959). In brief, the total 
number of writhes after intraperitoneal (i.p.) administration of 
1.2% (v/v) acetic acid (0.01 ml/g) was recorded over a period 
of 30 minutes, beginning immediately after injection. 
The formalin test
In order to discriminate between inflammatory and non-
inflammatory activities of the plant extract, different groups 
were treated orally with vehicle, water, morphine or extract 
(at increasing doses) 60 min before the subplantar injection 
of formalin. Formalin-induced behaviour was assessed as 
previously described by Hunskaar et al. (1986). Mice received 
a subplantar injection of 0.02 ml of formalin (2.5% v/v) at the 
dorsal surface of the left hind paw. The mice were immediately 
placed into an individual observation chamber, and the time (s) 
that the animal spent licking the injected paw was recorded. 
The nociceptive response includes two phases. The first phase 
is the neurogenic pain response, and it was recorded during 
the first 5 min after formalin injection. The second phase is the 
inflammatory response, and it was recorded 15-30 min after 
formalin injection. In order to evaluate the contribution of the 
different endogenous systems over the anti-nociceptive activity 
of the extract, experimental groups that received specific 
antagonists prior to administration of the extract were used.
The tail flick test
In order to evaluate the central anti-nociceptive effect of 
the plant extract, different groups were treated orally with 
vehicle, water, morphine or extract (at increasing doses). The 
test was performed as described by D’amour & Smith (1941). 
The animals were immobilized on the tail flick apparatus. A 
heat beam was focused at about 2 cm from the tip of the tail, 
and the latency before the tail flick, the reaction time (RT), 
was recorded automatically. The intensity of the heat source 
was adjusted to achieve baseline RT values after 3-5 s and 
was maintained for the remainder of the experiment. Animals 
presenting baseline values outside these limits were excluded 
from the experiment. Two measurements were recorded 
before substances (water, morphine, vehicle and extract) 
were administered, and six measurements were recorded at 
20 min intervals after the application of substances. In order to 
evaluate the contribution of different endogenous systems on 
the anti-nociceptive activity of the extract experimental groups 
that received specific antagonists prior to administration 
of the extract were used. The mean RT obtained before 
administration of substances was considered the baseline (BL). 
Anti-nociception was quantified as the percentage increase 
over the baseline shown in each measurement time, calculated 
using the following formula: 
 Increase in baseline (%) =  
RT x 100
   -100
                           BL
The paw oedema test
In order to evaluate the anti-oedematogenic effect of the plant 
extract, different groups were treated orally with vehicle, 
water, dexamethasone or extract (at increasing doses). Mouse 
paw oedema was induced by subplantar injection of 0.02 ml of 
carrageenan (2%) onto one of the hind paws. As a control, 0.02 
ml of distilled water was injected into the contralateral paw. 
Oedema was measured plethysmographically (Ferreira, 1979). 
Vehicle, water or extract were administered (p.o.) 60 min before 
the injection and dexamethasone was administered (s.c.) 20 
min before the injection. Oedema paw was measured at 1, 2, 
3 and 4 h after the injection of carrageenan, and the results 
were expressed as the increase in carrageenan-injected paw 
volume (μl) minus the volume of the water-injected paw. In 
order to evaluate the contribution of different endogenous 
systems on the anti-oedematogenic activity of the extract 
experimental groups that received specific antagonists prior 
to administration of the extract were used.
The open-field test
In order to evaluate the motor impairment induced by plant 
extract, different groups were treated orally with vehicle, 
water, morphine or extract (at increasing doses). Five days 
before behavioural testing, each animal was handled daily 
for a few minutes. The procedure followed was similar to the 
method described by Barros et al. (1991). The mice received 
vehicle, water, morphine or extract orally and were placed 
individually in an observation chamber (60 min after oral 
administration) the floor of which was divided into 50 squares 
(5 × 5 cm). The total number of squares crossed by the animals 
in a 5 min interval was counted. 
In vivo toxicological evaluation 
An acute toxicity test was performed according to the WHO 
(2000) and the Organization of Economic Co-operation and 
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Groups
Time of licking(s) 
(mean ± SEM)
First phase Second phase
Control 53.2 ± 6.3 175.2 ± 15
Vehicle (p.o.) 50.8 ± 3.6 173.9 ± 7.8
Morphine (p.o.) 33.5 ± 4.6a 84.8 ± 4.2a
SM 50 mg/kg (p.o.) 43.7 ± 6.4 139.0 ± 17.7a
SM 100 mg/kg (p.o.) 46.0 ± 2.6 126.9 ± 7.9a
SM 300 mg/kg (p.o.) 45.2 ± 6.6 102.3 ± 21.2a
SM 500 mg/kg (p.o.) 39.8 ± 4.0a 88.7 ± 16.2a
SM 500 mg/kg (p.o.) + naloxone (i.p.; 5 mg/kg) 38.7 ± 4.5a 89.4 ± 7.2a
SM 500 mg/kg (p.o.) + atropine (i.p.;10 mg/kg) 36.4 ± 5.1a 91.1 ± 8.0a
SM 500mg/kg (p.o.) + mecamylamine  
(i.p.; 10 mg/kg)
39.5 ± 4.3a 87.7 ± 9.1a
SM 500 mg/kg (p.o.) + L-NAME (i.p.; 20 mg/kg) 22.8 ± 4.0a,b 53.7 ± 6.2a,b
SM 500 mg/kg (p.o.) + L-arginine  
(i.p.; 40 mg/kg)
52.7 ± 6.0,b 138.3 ± 16.3b
Naloxone (i.p.; 5 mg/kg) 54.1 ± 5.2 176.4 ± 18.4
Atropine (i.p.; 10 mg/kg) 50.3 ± 4.7 172.4 ± 18.0
Mecamylamine (i.p.; 10 mg/kg) 48.7 ± 4.1 169.7 ± 8.7
L-NAME (i.p.; 20 mg/kg) 48.6 ± 5.8 165.9 ± 12.1
L-Arginine (i.p.; 40 mg/kg) 50.7 ± 6.1 167.4 ± 14.0
ap < 0.05, when compared with the control group. 
bp < 0.05, when compared with SM-treated group (500 mg/kg), 
calculated by One-way ANOVA followed by Bonferroni’s test.
Table 1 
Effect of hydroethanolic extract of Sidastrum micranthum 
(SM) by individual oral administration or in combination 
with antagonists, over formalin-induced licking.
Development (OECD) guidelines for chemical testing (2001). 
The hydroethanolic extract of Sidastrum micranthum was 
administered orally at increasing doses up to 2000 mg/kg. 
Animal behaviour was observed starting 5 h after a single 
administration of the compound and monitored daily until the 
14th day. Acute toxicity was expressed by the required dose in 
g/kg body weight to cause death in 50% of the animals tested 
(LD50).
Statistical analysis
All experimental groups consisted of 7-10 animals. The 
results are presented as the mean ± SEM. Statistical 
significance between groups was determined by a one-
way analysis of variance (ANOVA) followed by Bonferroni’s 
test for acetic acid-induced abdominal writhing, formalin 
and open field tests; and statistical significance between 
groups was determined by a two-way analysis of variance 
(ANOVA) followed by Bonferroni’s test for tail-flick and paw 




The results of the chemical tests performed in the preliminary 
phytochemical screening revealed the presence of flavonoids, 
triterpenes, steroids and phenolic acids in the hydroethanolic 
leaf extract of Sidastrum micranthum.
Effect of Sidastrum micranthum extract on the acetic acid-
induced writhing test
Intraperitoneal injection of acetic acid (1.2%) induced an 
average of 54.2 ± 6.1 writhes in a period of 30 min. The extract 
induced a dose-dependent anti-nociceptive effect on the 
writhing results. Doses of 50, 100, 300 and 500 mg/kg inhibited 
writhing by 49.8, 65.9, 71.9 and 83.4%, respectively. Morphine 
(5.01 mg/kg) inhibited the number of writhes by approximately 
50% in relation to control group (Fig. 1). 
Effect of Sidastrum micranthum extract on the formalin-induced 
licking test
Pre-treatment with S. micranthum extract significantly reduced 
the time subjects spent licking the injected paw, in both the 
first and the second phase after formalin injection. In the first 
phase, the inhibitory effect was observed only with the highest 
dose (500 mg/kg), whereas the second phase was inhibited at 
all doses (Table 1).
In the first phase, the extract showed 25.24% inhibition 
at dose of 500 mg/kg. In the second phase, the percentage 
of inhibition at the doses of 50, 100, 300, 500 mg/kg was 
20.66, 27.57, 41.61, 49.38%, respectively (Table 1). Morphine 
(5.01 mg/kg) inhibited the number of licks by approximately 
50% in relation to control group in both the first and second 
phases.
Fig. 1 - The effects of orally administered hydroethanolic 
extract of Sidastrum micranthum in the acetic acid-induced 
writhing. The mice were pretreated with water, vehicle, 
morphine (5.01 mg/kg) or the S. micranthum extract (50, 
100, 300 and 500 mg/kg) 60 min before the acetic acid 
intraperitoneal injection. The results are expressed as the 
mean ± SEM (n = 7-10). The statistical significance was 
calculated by one-way ANOVA followed by Bonferroni’s test. 
*p < 0.05, when comparing the S. micranthum, vehicle- and 
morphine-treated group with the control group.
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Evaluation of mechanism of action on the formalin-induced 
licking test
In Fig. 2, S. micranthum extract was administered in association 
with increasing doses of L-NAME and L-arginine to determine 
the lowest dose capable of producing a change in the anti-
nociceptive activity of extract. The same procedure was adopted 
for naloxone, mecamylamine and atropine (data not shown).
In both phases (Table 1) the isolated use of the antagonists 
naloxone, atropine and mecamylamine produced similar 
results to those obtained with the control and vehicle groups, 
whereas the concomitant use of these antagonists with S. 
micranthum extract produced results similar to those obtained 
with extract alone.
Table 1 shows that L-arginine and L-NAME, administered 
alone, did not produce significant effects relative to the control 
and vehicle groups. However, L-NAME administered with S. 
micranthum extract enhanced the anti-nociceptive effect of 
extract, and L-arginine reduced the anti-nociceptive effect 
of extract, in both phases.
Effect of Sidastrum micranthum extract on the tail-flick test
Fig. 3A shows the anti-nociceptive effect of the extract on 
the tail-flick test. An effect of the extract was observed only 
at higher doses (300 and 500 mg/kg), with a percentage of 
maximal effect of 30.26% at a dose of 300 mg/kg and 36.03% 
at 500 mg/kg. 
In this model, the effects of L-arginine and L-NAME, used 
alone, were not significantly different from those of control 
and vehicle groups. The previous administration of L-arginine 
partially reduced the effect of S. micranthum extract, whereas 
the previous administration of L-NAME increased the anti-
nociceptive effect of extract (Fig. 3B and 3C).
Effect of Sidastrum micranthum extract on the paw oedema test
In the paw oedema test induced by carrageenan, the effect 
was observed only with the highest dose (500 mg/kg) of S. 
micranthum extract and dexamethasone (2.25 mg/kg, s.c.). 
(Table 2)
The effects of L-arginine and L-NAME, used alone, were not 
significantly different from those of control and vehicle groups. 
The previous administration of L-arginine reduced the effect 
of S. micranthum extract on the first, second, and fourth hour 
of the model, whereas the previous administration of L-NAME 
increased the anti-nociceptive effect of extract in all times 
analysed (Table 2).
Effect of Sidastrum micranthum extract on the open-field test
The extract had no significant effect on locomotor activity, 
relative to the control and vehicle groups at dose of 500 mg/kg 
(Fig. 4) or with another dose tested (data not shown), whereas 
morphine significantly decreased locomotor activity (Fig. 4).
Toxicological evaluation of Sidastrum micranthum extract
The hydroethanolic extract of S. micranthum described in this 
paper was evaluated for acute toxicity in mice. No intoxication 
symptoms (disorientation, hyperactivity, piloerection or 
hyperventilation) were observed in the animals. The extract 
was not toxic after oral administration (LD50 > 2000 mg/kg).
Discussion
The present study aimed to evaluate the anti-nociceptive 
activity of the hydroethanolic extract of Sidastrum micranthum 
Fig. 2 - Evaluation of the antagonist dose used concurrently 
with oral administration of Sidastrum micranthum extract 
in the formalin test. A. The mice were pretreated 
intraperitoneally with L-arginine (10, 20, 30 and  
40 mg/kg) 15 min before the administration of extract or 
L-NAME. The dose of extract used was 500 mg/kg, dose 
of L-NAME was 40 mg/kg. B. The mice were pretreated 
intraperitoneal with L-NAME (3, 5, 10 and 20 mg/kg) 15 min 
before the administration of extract. The dose of extract 
used was 500 mg/kg. The results are presented as the mean 
± SEM (n = 7-10). The statistical significance was calculated 
using One-way ANOVA, followed by Bonferroni’s test. *p < 0.05,  
when comparing the group administered S. micranthum 
alone with the S. micranthum + antagonist-treated groups. 
#p < 0.05, when comparing the group administered L-NAME 
alone in the L-NAME + L-arginine-treated group.
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(A. St.-Hil.) Fryxell, Malvaceae, in models of acute pain and 
oedema formation in mice. These studies provide a foundation 
for the pharmacological study of this plant species in treating 
pain and inflammation. 
The acetic acid-induced abdominal writhing test has 
been used as a screening tool for assessing analgesic or anti-
inflammatory agents. Acetic acid induces an inflammatory 
response in the abdominal cavity, with subsequent activation 
of nociceptors (Collier et al., 1968), and acetic acid- induced 
constriction is considered a non-selective anti-nociceptive 
model (Bighetti et al., 1999; Sanchez-Mateo et al., 2006). The 
extract reduced the number of writhes, implying that it had 
a significant anti-nociceptive effect. However, this test was 
unable to ascertain whether the antinociception was related 
to inflammatory or non-inflammatory effects.
The extract also produced anti-nociceptive effects in both 
phases of the formalin test in mice, but only with the highest 
dose (500 mg/kg) during the first phase. The advantage of 
the formalin model of nociception is that it can discriminate 
between inflammatory and non-inflammatory components 
of pain.
This first phase lasts for a few minutes and reflects the 
neurogenic component of nociception, being reduced mainly 
by opioid-like drugs. The inflammatory component of the 
nociceptive response (second phase) starts after a silent period 
of 10-15 min and is produced by the release of mediators, such 
as bradykinin, histamine, sympathomimetic amines, tumour 
necrosis factor-’  and interleukins (Hama and Menzaghi, 2001; 
Hong and Abbott, 1996; Jourdan et al., 1997; Parada et al., 2001). 
In addition, local levels of prostaglandins are responsible for 
nociception progress and are the target of most non-steroidal 
anti-inflammatory drugs (NSAID) (Ferreira, 2002). 
The reduction of the time of licking in both phases of 
measurement indicates that the extract exerts anti-nociceptive 
effects on both inflammatory and non-inflammatory pain. This 
is consistent with the action of centrally acting analgesics 
while peripherally acting analgesics which act only during the 
second phase of the model (Le Bars et al., 2001). 
Naloxone acts by competitively binding to opiate receptors. 
Naloxone shows the maximum affinity towards the μ receptor, 
but also shows antagonistic activity at the κ and δ receptors 
(Handal et al., 1983). The previous administration of naloxone 
did not alter the effect produced by the extract, precluding the 
participation of opioid system.
Several lines of evidence show that the cholinergic system 
has broad therapeutic potential for the treatment of many 
clinically relevant pain states including inflammatory, 
neuropathic, visceral pain and pain because of arthritis 
(Jones and Dunlop, 2007). The previous administration of 
mecamylamine (a nonselective nicotinic acetylcholine 
receptor) and atropine (a nonselective muscarinic acetylcholine 
receptor) was used to evaluate the role of the nicotinic and 
muscarinic receptors, respectively, in the anti-nociceptive 
activity shown by S. micranthum extract. The results show that 
the muscarinic and nicotinic receptors are not involved in the 
effect of the extract, because pretreatment with atropine and 
mecamylamine did not alter the anti-nociceptive activity of 
the extract.
NO is an important mediator of nociception and it is 
unequivocally involved in central sensitization; it is also 
a signaling molecule that plays an important role in acute 
(Toriyabe et al., 2004) and chronic (Chen et al., 2010) pain 
states at both the central (Freire et al., 2009) and the peripheral 
(Omote et al., 2001) levels. However, experimental and clinical 
evidences have demonstrated that NO is also capable of 
inducing analgesia. Taken together, these data indicate that 
NO plays a complex and diverse role in the modulation of 
nociceptive processing.
Chen et al. (2010) recently demonstrated that pretreatment 
with L-NAME (non-selective NOS inhibitor), 7-nitroindazole 
(selective nNOS inhibitor), aminoguanidine hydrochloride 
(selective iNOS inhibitor), but not L-N(5)-(1-iminoethyl)-
ornithine (L-NIO, selective eNOS inhibitor), significantly 
attenuated thermal hyperalgesia induced by subplantar 
injection of complete Freund’s adjuvant (CFA) in mice. 
The subplantar (s.p.) injection of carrageenan and formalin 
causes the production and release of NO at the injured site 
(Omote et al., 2001). Previous administration of L-NAME (an NO 
synthase inhibitor) or L-arginine (a substrate of NO synthase) in 
the formalin test potentiated or inhibited the anti-nociceptive 
effect of S. micranthum extract, respectively. The use of an 
NO synthase inhibitor (L-NAME) enhances the effect of the 
compound by reducing the synthesis of NO, which acts as 
a retrograde messenger at the spinal level to increase the 
stimulatory neurotransmitters released (Oess et al., 2006). In 
contrast, L-arginine increases the concentration of NO at the 
spinal level and thus reduces the anti-nociceptive effect of the 
extract. These results show that the production and release 
of NO is important to the effect of the extract. On the basis of 
these results, we believe that S. micranthum extract can reduce 
the concentration of NO at the spinal level.
Tail flicking is predominantly a spinal reflex and is 
considered to be selectively sensitive to centrally acting 
analgesic compounds (Ramabadran et al., 1989). In the tail-flick 
test, the thermal stimulation activates peripheral nociceptors, 
leading to reflexive removal of the tail (Kuraishi et al., 1983). 
The anti-nociceptive effect of the extract was also observed in 
the tail-flick test with the highest doses (300 and 500 mg/kg) 
confirming its central activity. 
This later peak effect of morphine can be explained by the 
irregular absorption of oral morphine (Tassinari et al., 1995). 
The profiles of the 300 and 500 mg/kg doses show two distinct 
phases of action, suggesting the possibility of existence of an 
active metabolite.
Although the oral morphine presents one-fourth to one-
sixth of bioavailability obtained in parenteral administration 
(Tassinari et al., 1995), the oral route was chosen to be the same 
route of administration used to the hydroethanolic extract 
of S. micranhum and thereby establish a better comparison 
between the standard drug (morphine) and test substance (S. 
micranhum extract).
The lack of effect on the first phase of the formalin test for 
the dose of 300 mg/kg, can be explained by the fact that the 
test was performed 1 h after the extract was administered, 
which is when the central activity of the extract decreases, 
as observed in the tail-flick test. The extract produced an 
anti-nociceptive effect, since it showed activity in the acetic 
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acid-induced abdominal writhing, formalin and tail-flick tests, 
where the stimulus is harmful. 
To evaluate a possible anti-inflammatory action of the 
extract, paw oedema was induced by carrageenan. Three 
phases have been postulated for carrageenan-induced 
oedema: histamine and 5-hydroxytryptamine (5-HT) release 
in the early phase (first hour), kinin release in the second 
phase (second hour) and prostaglandin release in the third 
phase (third and fourth hours) (Olajide et al., 1999). In this 
test, the extract inhibited the induction of paw oedema 
in all phases, thus demonstrating its anti-oedematogenic 
activity.
The L-arginine-NO pathway has been proposed to play 
an important role in the carragenan-induced inflammatory 
response (Cuzzocrea et al., 1996), and the expression of the 
inducible isoform of NO synthase has been proposed as an 
important mediator of inflammation (Pan et al., 2009). The 
administration of L-NAME or L-arginine in the paw oedema 
test, potentiated or inhibited the carragenaan-mediated paw 
oedema formation from the administration of S. micranthum 
extract, respectively. 
We suggest that the anti-inflammatory mechanism of the 
extract may be through the L-arginine-NO pathway due to the 
influence of NO production on the anti-oedematogenic effect 
of the extract, as demonstrated by pretreatment with L-NAME 
and L-arginine.
The open ﬁeld test was used to exclude the possibility 
that the anti-nociceptive action of extract could be related 
to nonspeciﬁc disturbances in the locomotor activity of the 
animals. We observed that with effective anti-nociceptive dose, 
the hydroethanolic extract of S. micranthum did not alter the 
motor performance of mice.
The anti-nociceptive and anti-oedematogenic action of 
the hydroethanolic extract of S. micranthum is reinforced by 
the results showing that acute administration of the extract 
inhibited carragenaan-mediated paw oedema formation and 
demonstrated activity in the tail flick test, formalin-induced 
paw licking test and acetic acid-induced abdominal writhing 
test. These data provide initial evidence that the traditional 
use of S. micranthum is effective at reducing pain and oedema 
formation. 
It is important to state that there are no descriptions of 
adverse effects or intoxication in humans following the use 
of S. micranthum extract in folk medicine. This lack of adverse 
effects and intoxication is corresponded in our study by the 
lack of physiological complications in the animals that received 
the extract orally.
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